Auranofin lethality to prostate cancer includes inhibition of proteasomal deubiquitinases and disrupted androgen receptor signaling

Ningning Liu, Zhiqiang Guo, Xiaohong Xia, Yuning Liao, Fangcheng Zhang, Chuyi Huang, Yuan Liu, Xiumei Deng, Lili Jiang, Xuejun Wang, Jinbao Liu, Hongbiao Huang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Auranofin (Aur) inhibits thioredoxin reductases and is also an inhibitor of 19S proteasome associated deubiquitinases, targeting USP14 and UCHL5. Androgen receptor is often over-expressed in prostate cancer (PCa) and is strongly linked to PCa growth and progression. Consequently, androgen deprivation therapy (ADT) that reduces androgen has been applied to treat androgen receptor-mediated PCa for decades. Nevertheless, most ADT treated patients experience relapse due to the development of the castration-resistant PCa. Numerous studies have shown that down-regulation of cellular androgen receptor level, including inhibiting its transcription and promoting its protein degradation, is lethal to PCa cells. Here we report that Aur arrested cell cycle progression and induced apoptosis of PCa cells. Co-inhibition of USP14 and UCHL5 with Aur facilitated the ubiquitination and degradation of androgen receptors in LNcap and 22RV1 PCa cells. Our results also show that Aur decreases the mRNA level of androgen receptors. In conclusion, our findings suggest that Aur is a promising agent for clinical translation to treat PCa.

Original languageEnglish (US)
Pages (from-to)1-11
Number of pages11
JournalEuropean Journal of Pharmacology
Volume846
DOIs
StatePublished - Mar 5 2019

Fingerprint

Auranofin
Androgen Receptors
Prostatic Neoplasms
Androgens
Thioredoxin-Disulfide Reductase
Proteasome Inhibitors
Deubiquitinating Enzymes
Ubiquitination
Castration
Proteolysis
Cell Cycle
Down-Regulation
Apoptosis
Recurrence
Messenger RNA

Keywords

  • Androgen receptor
  • Auranofin
  • Deubiquitinase inhibitor
  • Prostate cancer

ASJC Scopus subject areas

  • Pharmacology

Cite this

Auranofin lethality to prostate cancer includes inhibition of proteasomal deubiquitinases and disrupted androgen receptor signaling. / Liu, Ningning; Guo, Zhiqiang; Xia, Xiaohong; Liao, Yuning; Zhang, Fangcheng; Huang, Chuyi; Liu, Yuan; Deng, Xiumei; Jiang, Lili; Wang, Xuejun; Liu, Jinbao; Huang, Hongbiao.

In: European Journal of Pharmacology, Vol. 846, 05.03.2019, p. 1-11.

Research output: Contribution to journalArticle

Liu, Ningning ; Guo, Zhiqiang ; Xia, Xiaohong ; Liao, Yuning ; Zhang, Fangcheng ; Huang, Chuyi ; Liu, Yuan ; Deng, Xiumei ; Jiang, Lili ; Wang, Xuejun ; Liu, Jinbao ; Huang, Hongbiao. / Auranofin lethality to prostate cancer includes inhibition of proteasomal deubiquitinases and disrupted androgen receptor signaling. In: European Journal of Pharmacology. 2019 ; Vol. 846. pp. 1-11.
@article{fde80ee5416b4ed0b8ac8282168d4cc4,
title = "Auranofin lethality to prostate cancer includes inhibition of proteasomal deubiquitinases and disrupted androgen receptor signaling",
abstract = "Auranofin (Aur) inhibits thioredoxin reductases and is also an inhibitor of 19S proteasome associated deubiquitinases, targeting USP14 and UCHL5. Androgen receptor is often over-expressed in prostate cancer (PCa) and is strongly linked to PCa growth and progression. Consequently, androgen deprivation therapy (ADT) that reduces androgen has been applied to treat androgen receptor-mediated PCa for decades. Nevertheless, most ADT treated patients experience relapse due to the development of the castration-resistant PCa. Numerous studies have shown that down-regulation of cellular androgen receptor level, including inhibiting its transcription and promoting its protein degradation, is lethal to PCa cells. Here we report that Aur arrested cell cycle progression and induced apoptosis of PCa cells. Co-inhibition of USP14 and UCHL5 with Aur facilitated the ubiquitination and degradation of androgen receptors in LNcap and 22RV1 PCa cells. Our results also show that Aur decreases the mRNA level of androgen receptors. In conclusion, our findings suggest that Aur is a promising agent for clinical translation to treat PCa.",
keywords = "Androgen receptor, Auranofin, Deubiquitinase inhibitor, Prostate cancer",
author = "Ningning Liu and Zhiqiang Guo and Xiaohong Xia and Yuning Liao and Fangcheng Zhang and Chuyi Huang and Yuan Liu and Xiumei Deng and Lili Jiang and Xuejun Wang and Jinbao Liu and Hongbiao Huang",
year = "2019",
month = "3",
day = "5",
doi = "10.1016/j.ejphar.2019.01.004",
language = "English (US)",
volume = "846",
pages = "1--11",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",

}

TY - JOUR

T1 - Auranofin lethality to prostate cancer includes inhibition of proteasomal deubiquitinases and disrupted androgen receptor signaling

AU - Liu, Ningning

AU - Guo, Zhiqiang

AU - Xia, Xiaohong

AU - Liao, Yuning

AU - Zhang, Fangcheng

AU - Huang, Chuyi

AU - Liu, Yuan

AU - Deng, Xiumei

AU - Jiang, Lili

AU - Wang, Xuejun

AU - Liu, Jinbao

AU - Huang, Hongbiao

PY - 2019/3/5

Y1 - 2019/3/5

N2 - Auranofin (Aur) inhibits thioredoxin reductases and is also an inhibitor of 19S proteasome associated deubiquitinases, targeting USP14 and UCHL5. Androgen receptor is often over-expressed in prostate cancer (PCa) and is strongly linked to PCa growth and progression. Consequently, androgen deprivation therapy (ADT) that reduces androgen has been applied to treat androgen receptor-mediated PCa for decades. Nevertheless, most ADT treated patients experience relapse due to the development of the castration-resistant PCa. Numerous studies have shown that down-regulation of cellular androgen receptor level, including inhibiting its transcription and promoting its protein degradation, is lethal to PCa cells. Here we report that Aur arrested cell cycle progression and induced apoptosis of PCa cells. Co-inhibition of USP14 and UCHL5 with Aur facilitated the ubiquitination and degradation of androgen receptors in LNcap and 22RV1 PCa cells. Our results also show that Aur decreases the mRNA level of androgen receptors. In conclusion, our findings suggest that Aur is a promising agent for clinical translation to treat PCa.

AB - Auranofin (Aur) inhibits thioredoxin reductases and is also an inhibitor of 19S proteasome associated deubiquitinases, targeting USP14 and UCHL5. Androgen receptor is often over-expressed in prostate cancer (PCa) and is strongly linked to PCa growth and progression. Consequently, androgen deprivation therapy (ADT) that reduces androgen has been applied to treat androgen receptor-mediated PCa for decades. Nevertheless, most ADT treated patients experience relapse due to the development of the castration-resistant PCa. Numerous studies have shown that down-regulation of cellular androgen receptor level, including inhibiting its transcription and promoting its protein degradation, is lethal to PCa cells. Here we report that Aur arrested cell cycle progression and induced apoptosis of PCa cells. Co-inhibition of USP14 and UCHL5 with Aur facilitated the ubiquitination and degradation of androgen receptors in LNcap and 22RV1 PCa cells. Our results also show that Aur decreases the mRNA level of androgen receptors. In conclusion, our findings suggest that Aur is a promising agent for clinical translation to treat PCa.

KW - Androgen receptor

KW - Auranofin

KW - Deubiquitinase inhibitor

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85060125399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060125399&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2019.01.004

DO - 10.1016/j.ejphar.2019.01.004

M3 - Article

C2 - 30639309

AN - SCOPUS:85060125399

VL - 846

SP - 1

EP - 11

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

ER -